Kevin Joseph Fitzgerald Sells 663 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald sold 663 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.21, for a total value of $169,204.23. Following the transaction, the executive vice president now directly owns 14,321 shares in the company, valued at approximately $3,654,862.41. The trade was a 4.42 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Kevin Joseph Fitzgerald also recently made the following trade(s):

• On Tuesday, February 18th, Kevin Joseph Fitzgerald sold 1,440 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $251.56, for a total value of $362,246.40.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY opened at $250.51 on Thursday. The business’s fifty day moving average price is $253.89 and its two-hundred day moving average price is $263.20. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The stock has a market capitalization of $32.43 billion, a price-to-earnings ratio of -115.44 and a beta of 0.35. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.94 EPS for the current fiscal year.

Institutional Trading of Alnylam Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Creative Planning lifted its stake in shares of Alnylam Pharmaceuticals by 24.6% during the third quarter. Creative Planning now owns 10,012 shares of the biopharmaceutical company’s stock valued at $2,754,000 after acquiring an additional 1,978 shares during the period. Bleakley Financial Group LLC lifted its stake in shares of Alnylam Pharmaceuticals by 24.7% during the third quarter. Bleakley Financial Group LLC now owns 2,215 shares of the biopharmaceutical company’s stock valued at $609,000 after acquiring an additional 439 shares during the period. Blue Trust Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 431.0% during the third quarter. Blue Trust Inc. now owns 462 shares of the biopharmaceutical company’s stock valued at $127,000 after acquiring an additional 375 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in shares of Alnylam Pharmaceuticals by 62.2% during the third quarter. Allspring Global Investments Holdings LLC now owns 420 shares of the biopharmaceutical company’s stock valued at $116,000 after acquiring an additional 161 shares during the period. Finally, Signaturefd LLC lifted its stake in shares of Alnylam Pharmaceuticals by 34.1% during the third quarter. Signaturefd LLC now owns 1,854 shares of the biopharmaceutical company’s stock valued at $510,000 after acquiring an additional 471 shares during the period. Institutional investors own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ALNY. Sanford C. Bernstein decreased their price target on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. Scotiabank cut their price target on Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating for the company in a research note on Friday, February 14th. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday, November 19th. HC Wainwright reissued a “buy” rating and issued a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, January 13th. Finally, Barclays raised their price objective on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $299.48.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.